Bing

SEARCH HISTORY

Merck & Co. (NYSE:MRK) had its target price lifted by Jefferies Group from $63.00 to $66.00 in a research note released on Thursday morning. They currently have a hold rating on the stock. In other Merck & Co. news …
Mideast Times · 5/23/2015
Regions Financial Corp (NYSE:RF), has the market capitalization of $ 13.70B. The stock has P/B ratio of 0.85while EPS was 0.73. Institutional ownership of the company was 75% while 1.34B shares were outstanding. Net profit margin of the Company was …
investorwired.com · 12 hours ago
Profit Margin
Investment analysts at Jefferies Group increased their target price on shares of Merck & Co. (NYSE:MRK) from $63.00 to $66.00 in a note issued to investors on Thursday. The firm currently has a “hold” rating on the stock. Jefferies Group’s price ...
Ticker Report · 5/21/2015
More from Bing News
Tornier N.V. (TRNX): TRNX stock is down 1.3% today. Zeltiq Aesthetics Inc (ZLTQ): ZLTQ stock is down 1.2% today. Merck & Company (MRK): MRK stock is down 1.2%, marking the third consecutive day the stock has decreased. Endologix Inc (ELGX) …
Investor Place · 5/22/2015
Year-to-date returns are based on May 20, 2015, closing prices. The highest-rated stock appears last. MRK data by YCharts 3. Merck & Co., Inc. (MRK - Get Report) Rating: B+ Market Cap: $170.8 billion Year-to-date return: 6.5% Merck & Co., Inc. provides ...
The Street · 5/21/2015
Pharmaceutical Stocks
MRK) Avelumab in lung cancer is unimpressive. The sell-side research firm reiterated a Reduce rating with a price objective of $30 on Pfizer stock. With news crossing the wires, Pfizer stock was last trading up 0.15% …
bidnessetc.com · 5/18/2015
The stock’s 52-week range is $116.32 to $158.83. Trading volume was about 25% below the daily average of around 4 million shares. The company had no specific news today. Merck & Co. Inc. (NYSE: MRK) traded …
24/7 Wall ST · 5/22/2015
Fears around biosimilars have weighed on Roche’s stock. Analogous to generic copies of pharmaceuticals ... Bristol-Myers Squibb BMY-0.86 % and Merck MRK-1.20 % & Co. of the U.S., are gaining ground. Roche …
Wall Street Journal · 10 hours ago
Roche
Merck (NYSE:MRK) is presenting plenty of new data on cancer drugs trials ... Keytruda Has Potential To Move Merck’s Stock We estimate that Keytruda could earn as much as $5 billion in annual revenues if it penetrates 10% of the advanced melanoma …
Trefis · 5/21/2015
In its most recent Dow 30 report, the firm provides some insight on Merck & Co., Inc. (NYSE: MRK). Weekly Chart View gallery Although Merck has been structurally “nice” for years, the stock ran up towards historic resistance levels. “Last time MRK ...
Yahoo Finance · 5/22/2015
Related Searches